BLS PHARMACEUTICALS LIMITED
ASX:BLSHousehold & Personal ProductsToday’s holders own 96.6% of what they think they own, once every option and right converts.
1 cash raise in 24 months; 2% of shares in the money; since relisting as BLS; prior history under BXN not included
Between August 2026 and October 2026, its latest share-count filing, BLS PHARMACEUTICALS LIMITED's ordinary share count rose 2.5% to 236M shares; these figures cover only the period since the company's rename from BXN. The company completed one capital raising in the past 24 months, a A$110K placement with director participation in December 2025. Options and rights on issue could convert into 8M new shares, equal to 3.6% of the current share count, of which 2% are in the money; the nearest expiry is March 2027. The company reported more than 4 quarters of funding at the recent spend rate from the September 2026 quarter. No proposed securities issues are currently pending.
Quick answers · 2
When did BLS last raise capital?
The last capital raise in BLS Pharmaceuticals's filings is Placement (director participation) of $110k announced 15 Dec 2025, one of 1 cash raises in 24 months.
When do BLS's options expire?
Unexercised options and rights equal 3.6% of BLS Pharmaceuticals's shares on issue; the nearest expiry is Mar 2027.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 26 Oct 2026 | 2A · quoted issue | BLS : ORDINARY FULLY PAID | 236.1M | Appendix 2A |
| 5 Oct 2026 | 2A · quoted issue | BLS : ORDINARY FULLY PAID | 231.0M | Appendix 2A |
| 28 Sept 2026 | 2A · quoted issue | BLS : ORDINARY FULLY PAID | 230.7M | Appendix 2A |
| 10 Sept 2026 | 2A · quoted issue | BLS : ORDINARY FULLY PAID | 230.5M | Appendix 2A |
| 4 Sept 2026 | 2A · quoted issue | BLS : ORDINARY FULLY PAID | 230.4M | Appendix 2A |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months · counted since relisting as BLS (6 July 2026); prior history under BXN is not included
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered5.0M · 2.1% of sharesOptions and warrants — they convert when the share price clears their exercise price.
- Condition-triggered3.4M · 1.5% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
Exercise price on record: 5.0M priced (of which 5.0M in the money), 3.4M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
At $1.01 today, 5.0M securities are in the money (2.1% of shares on issue). No price up to ten times today’s switches on any more priced supply.
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 3.4M (40.8% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| BLSAG | Options | Price-triggered | $0.10 | 26 Mar 2027 | 100k | Filing |
| BLSAF | Options | Price-triggered | $0.44 | 26 Mar 2027 | 1.5M | Filing |
| BLSAE | Options | Price-triggered | $0.50 | 26 Mar 2027 | 3.4M | Filing |
| BLSAC | Performance rights | Condition-triggered | — | — | 3.4M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | Mr Jason Hine | Other incentive | 700k | 20 | 1.0M | — | 3Y notice |
| 23 Oct 2026 | Mr Samuel Watson | Other incentive | 2.7M | — | 3.9M | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.